中国老年人C反应蛋白-甘油三酯-葡萄糖指数与老年良性前列腺增生患者下尿路症状之间的关系:一项全国纵向队列研究

doi:10.3969/j.issn.1003-9198.2026.04.002

摘要/Abstract

摘要： 目的探究C反应蛋白-甘油三酯-葡萄糖指数(CTI)与老年良性前列腺增生/下尿路症状(BPH/LUTS)风险之间的关联。方法本研究使用2011—2018年中国健康与养老追踪调查(CHARLS)纵向队列的数据,包括3610名中老年参与者。使用多变量Cox比例风险回归模型、Kaplan-Meier生存分析和限制性立方样条(RCS)探究CTI水平与BPH/LUTS风险之间的关系,并通过ROC曲线分析评估CTI的预测性能。此外,进行亚组分析和敏感性分析以评估结果的稳定性。结果在随访期间,共有630名(17.5%)参与者发生BPH/LUTS。在对潜在混杂因素进行调整后,CTI水平每增加1个单位,BPH/LUTS风险增加8%(HR=1.08, 95%CI:1.03~1.25)。与最低CTI四分位数相比,CTI较高的四分位数与BPH/LUTS风险的相关性逐渐增加(HR=1.23、1.29、1.38; P_趋势=0.018)。亚组分析表明,在BMI≥24的参与者中,CTI水平与BPH/LUTS风险的相关性更强。RCS分析进一步支持CTI水平和BPH/LUTS风险之间的总体线性关系。此外,ROC曲线分析表明,CTI具有比甘油三酯-葡萄糖指数(TyG)和CRP更强的BPH/LUTS风险预测性能。敏感性分析证明了这些主要发现的稳定性。结论 CTI水平与中老年男性BPH/LUTS风险呈显著正相关。此外,这种关联在不同BMI人群之间表现出差异。维持较低的CTI水平可能有助于降低中老年男性BPH/LUTS发生风险。

关键词: 良性前列腺增生, 下尿路症状, C反应蛋白-甘油三酯-葡萄糖指数, 中国健康与养老追踪调查

Abstract: Objective To investigate the association between C-reactive protein-triglyceride-glucose index (CTI) and the risk of developing lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS). Methods This study utilized data from the China Health and Retirement Longitudinal Study (CHARLS) longitudinal cohort from 2011 to 2018, which included 3610 middle-aged and older participants. Multivariable Cox proportional hazards regression models, Kaplan-Meier survival analysis, and restricted cubic splines (RCS) were used to explore the relationship between CTI level and the risk of BPH/LUTS. The predictive performance of CTI was assessed using receiver operating characteristic (ROC) curve analysis. Additionally, subgroup analysis and sensitivity analysis were conducted to evaluate the robustness of the findings. Results During the follow-up period, 630 participants (17.5%) developed BPH/LUTS. After adjusting for potential confounders, each one-unit increase in CTI level was associated with an 8% increased risk of BPH/LUTS (HR=1.08, 95%CI: 1.03-1.25). Compared to the lowest quartile, higher quartiles of CTI were associated with progressively increasing risks of BPH/LUTS (HRs=1.23, 1.29, 1.38, P for trend=0.018). Subgroup analysis indicated that the association between CTI level and BPH/LUTS risk was stronger among participants with a body mass index (BMI) ≥24. RCS analysis further supported an overall linear relationship between CTI level and BPH/LUTS risk. Furthermore, ROC analysis showed that CTI had a stronger predictive performance for BPH/LUTS risk compared to triglyceride-glucose index (TyG) and C-reaction protein alone. Sensitivity analysis confirmed the robustness of these primary findings. Conclusions This study indicates that CTI level are significantly and positively associated with the risk of BPH/LUTS in middle-aged and older men. Moreover, this association varies across different BMI populations. Maintaining lower CTI level may help reduce the risk of BPH/LUTS in middle-aged and older men.

Key words: benign prostatic hyperplasia, lower urinary tract symptoms, C-reactive protein-triglyceride-glucose index, China Health and Retirement Longitudinal Study

中图分类号:

R 691.2

徐学渊, 刘博涵, 冯师健, 罗德毅. 中国老年人C反应蛋白-甘油三酯-葡萄糖指数与老年良性前列腺增生患者下尿路症状之间的关系:一项全国纵向队列研究[J]. 实用老年医学, 2026, 40(4): 332-339.

XU Xueyuan, LIU Bohan, FENG Shijian, LUO Deyi. Relationship between C-reactive protein-triglyceride-glucose index and lower urinary tract symptoms due to benign prostatic hyperplasia in Chinese older adults: a nationwide longitudinal cohort study[J]. Practical Geriatrics, 2026, 40(4): 332-339.

参考文献

[1] WANG W, GUO Y, ZHANG D, et al. The prevalence of benign prostatic hyperplasia in mainland China:evidence from epidemiological surveys[J]. Sci Rep, 2015, 5:13546.
[2] DEVLIN C M, SIMMS M S, MAITLAND N J. Benign prostatic hyperplasia - what do we know?[J]. BJU Int, 2021, 127(4):389-399.
[3] DORNBIER R, PAHOUJA G, BRANCH J, et al. The New American Urological Association Benign Prostatic Hyperplasia Clinical Guidelines:2019 Update[J]. Curr Urol Rep, 2020, 21(9):32.
[4] TAUB D A, WEI J T. The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States[J]. Curr Urol Rep, 2006, 7(4):272-281.
[5] XU X F, LIU G X, GUO Y S, et al. Global, regional, and national incidence and year lived with disability for benign prostatic hyperplasia from 1990 to 2019[J]. Am J Mens Health, 2021, 15(4):15579883211036786.
[6] OTTAIANO N, SHELTON T, SANEKOMMU G, et al. Surgical complications in the management of benign prostatic hyperplasia treatment[J]. Curr Urol Rep, 2022, 23(5):83-92.
[7] LIM K B. Epidemiology of clinical benign prostatic hyperplasia[J]. Asian J Urol, 2017, 4(3):148-151.
[8] GACCI M, CORONA G, SEBASTIANELLI A, et al. Male lower urinary tract symptoms and cardiovascular events:a systematic review and meta-analysis[J]. Eur Urol, 2016, 70(5):788-796.
[9] XIA M F, CHEN Y, LIN H D, et al. A indicator of visceral adipose dysfunction to evaluate metabolic health in adult Chinese[J]. Sci Rep, 2016, 6:38214.
[10] SUN Y, JI H, SUN W, et al. Triglyceride glucose (TyG) index:a promising biomarker for diagnosis and treatment of different diseases[J]. Eur J Intern Med, 2025, 131:3-14.
[11] TAO L C, XU J N, WANG T T, et al. Triglyceride-glucose index as a marker in cardiovascular diseases:landscape and limitations[J]. Cardiovasc Diabetol, 2022, 21(1):68.
[12] FU X, WANG Y, LU Y, et al. Association between metabolic syndrome and benign prostatic hyperplasia:the underlying molecular connection[J]. Life Sci, 2024, 358:123192.
[13] XU G, DAI G, HUANG Z, et al. The etiology and pathogenesis of benign prostatic hyperplasia:the roles of sex hormones and anatomy[J]. Res Rep Urol, 2024, 16:205-214.
[14] HUO G, TANG Y, LIU Z, et al. Association between C-reactive protein-triglyceride glucose index and stroke risk in different glycemic status:insights from the China Health and Retirement Longitudinal Study (CHARLS)[J]. Cardiovasc Diabetol, 2025, 24(1):142.
[15] CHUGHTAI B, LEE R, TE A, et al. Inflammation and benign prostatic hyperplasia:clinical implications[J]. Curr Urol Rep, 2011, 12(4):274-277.
[16] NEGI S K, DESAI S, FAUJDAR G, et al. The correlation between obesity and prostate volume in patients with benign prostatic hyperplasia:a prospective cohort study[J]. Urologia, 2024, 91(3):512-517.
[17] HOTAMISLIGIL G S. Inflammation, metaflammation and immunometabolic disorders[J]. Nature, 2017, 542(7640):177-185.
[18] ZHANG L, LI S, LIU D, et al. The relationship between C-reactive protein-triglyceride-glucose index and cardiovascular disease:insights from the China health and retirement longitudinal study (CHARLS)[J]. Cardiovasc Diabetol, 2025, 24(1):410.
[19] ZHAO D F. Value of C-reactive protein-triglyceride glucose index in predicting cancer mortality in the general population:results from national health and nutrition examination survey[J]. Nutr Cancer, 2023, 75(10):1934-1944.
[20] HUANG C, YOU H, ZHANG Y, et al. Association between C-reactive protein-triglyceride glucose index and depressive symptoms in American adults:results from the NHANES 2005 to 2010[J]. BMC Psychiatry, 2024, 24(1):890.
[21] SHAN Y, LIU Q, GAO T. Application of the C-reactive protein-triglyceride glucose index in predicting the risk of new-onset diabetes in the general population aged 45 years and older:a national prospective cohort study[J]. BMC Endocr Disord, 2025, 25(1):126.
[22] DAHER M, SAQER T, JABR M, et al. Benign prostatic hyperplasia and metabolic syndrome; prevalence and association:a cross-sectional study in Syria[J]. BMC Urol, 2023, 23(1):187.
[23] LI B, ZHANG Z, SUN C, et al. Association between TyG-BMI and BPH in a national prospective cohort study[J]. Sci Rep, 2025, 15(1):8743.
[24] MISHRA V C, ALLEN D J, NICOLAOU C, et al. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia?[J]. BJU Int, 2007, 100(2):327-331.
[25] ST SAUVER J L, SARMA A V, JACOBSON D J, et al. Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort[J]. Am J Epidemiol, 2009, 169(11):1281-1290.
[26] GAO A, PENG B, GAO Y, et al. Evaluation and comparison of inflammatory and insulin resistance indicators on recurrent cardiovascular events in patients undergoing percutaneous coronary intervention:a single center retrospective observational study[J]. Diabetol Metab Syndr, 2025, 17(1):157.
[27] CUI C, LIU L, QI Y, et al. Joint association of TyG index and high sensitivity C-reactive protein with cardiovascular disease:a national cohort study[J]. Cardiovasc Diabetol, 2024, 23(1):156.
[28] WAN B, WANG S, HU S, et al. The comprehensive effects of high-sensitivity C-reactive protein and triglyceride glucose index on cardiometabolic multimorbidity[J]. Front Endocrinol:Lausanne, 2025, 16:1511319.
[29] XIONG Y, ZHANG Y, LI X, et al. The prevalence and associated factors of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in aging males[J]. Aging Male, 2020, 23(5):1432-1439.
[30] LIAO G, LEE P M Y, ZHAO S, et al. Joint effect between bisphenol A and alcohol consumption on benign prostatic hyperplasia:a case-control study in Hong Kong Chinese males[J]. Prostate, 2021, 81(15):1214-1224.
[31] CHUGHTAI B, FORDE J C, THOMAS D D, et al. Benign prostatic hyperplasia[J]. Nat Rev Dis Primers, 2016, 2:16031.
[32] LI B H, DENG T, HUANG Q, et al. Body mass index and risk of prostate volume, international prostate symptom score, maximum urinary flow rate, and post-void residual in benign prostatic hyperplasia patients[J]. Am J Mens Health, 2019, 13(4):1557988319870382.
[33] WANG S, MAO Q, LIN Y, et al. Body mass index and risk of BPH:a meta-analysis[J]. Prostate Cancer Prostatic Dis, 2012, 15(3):265-272.
[34] WANG Y B, YANG L, DENG Y Q, et al. Causal relationship between obesity, lifestyle factors and risk of benign prostatic hyperplasia:a univariable and multivariable Mendelian randomization study[J]. J Transl Med, 2022, 20(1):495.